These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 21692703)

  • 1. Clinical trials of vaccines for immunotherapy in pancreatic cancer.
    Plate J
    Expert Rev Vaccines; 2011 Jun; 10(6):825-36. PubMed ID: 21692703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current immunotherapeutic strategies in pancreatic cancer.
    Plate JM
    Surg Oncol Clin N Am; 2007 Oct; 16(4):919-43, xi. PubMed ID: 18022552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospects for vaccine therapy for pancreatic cancer.
    Gaudernack G
    Best Pract Res Clin Gastroenterol; 2006 Apr; 20(2):299-314. PubMed ID: 16549329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunologic approaches to the management of pancreatic cancer.
    Laheru D; Biedrzycki B; Jaffee EM
    Cancer J; 2001; 7(4):324-37. PubMed ID: 11561608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer vaccines: an update with special focus on ganglioside antigens.
    Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE
    Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in therapeutic vaccines for pancreatic cancer.
    Plate JM
    Discov Med; 2012 Aug; 14(75):89-94. PubMed ID: 22935205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The development of a novel cancer vaccine using Peptide vaccine for patients with advanced pancreatic cancer].
    Miyazawa M; Yamaue H
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):1903-5. PubMed ID: 22202233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune responses to human tumors: development of tumor vaccines.
    Platsoucas CD; Fincke JE; Pappas J; Jung WJ; Heckel M; Schwarting R; Magira E; Monos D; Freedman RS
    Anticancer Res; 2003; 23(3A):1969-96. PubMed ID: 12894571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials.
    Mosolits S; Nilsson B; Mellstedt H
    Expert Rev Vaccines; 2005 Jun; 4(3):329-50. PubMed ID: 16026248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Challenge of Developing New Therapies for Childhood Cancers.
    Balis FM
    Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C; Sanda MG
    Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colorectal cancer vaccines in clinical trials.
    Speetjens FM; Zeestraten EC; Kuppen PJ; Melief CJ; van der Burg SH
    Expert Rev Vaccines; 2011 Jun; 10(6):899-921. PubMed ID: 21692708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A clinical development paradigm for cancer vaccines and related biologics.
    Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
    J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors.
    Kudo-Saito C; Schlom J; Camphausen K; Coleman CN; Hodge JW
    Clin Cancer Res; 2005 Jun; 11(12):4533-44. PubMed ID: 15958639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccine therapy of established tumors in the absence of autoimmunity.
    Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J
    Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased immunogenicity of tumor-associated antigen, mucin 1, engineered to express alpha-gal epitopes: a novel approach to immunotherapy in pancreatic cancer.
    Deguchi T; Tanemura M; Miyoshi E; Nagano H; Machida T; Ohmura Y; Kobayashi S; Marubashi S; Eguchi H; Takeda Y; Ito T; Mori M; Doki Y; Sawa Y
    Cancer Res; 2010 Jul; 70(13):5259-69. PubMed ID: 20530670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer vaccines: a critical review on clinical impact.
    Bitton RJ
    Curr Opin Mol Ther; 2004 Feb; 6(1):17-26. PubMed ID: 15011777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-small-cell lung carcinoma vaccines in clinical trials.
    Rossi A; Maione P; Schettino C; Bareschino MA; Sacco PC; Ambrosio R; Barbato V; Zeppa R; Palazzolo G; Gridelli C
    Expert Rev Vaccines; 2011 Jun; 10(6):887-97. PubMed ID: 21692707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting.
    Gray A; Raff AB; Chiriva-Internati M; Chen SY; Kast WM
    Immunol Rev; 2008 Apr; 222():316-27. PubMed ID: 18364011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.